Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 362, Issue 1482, 2007, Pages 959-971

  Zhou, Guang Biao ^a,b   Zhang, Ji ^a,c   Wang, Zhen Yi ^a   Chen, Sai Juan ^a   Chen, Zhu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Acute promyelocytic leukaemia; all trans retinoic acid; Apoptosis; Arsenic trioxide; Differentiation; Synergy

Indexed keywords

APOPTOSIS; CANCER; CHEMOTHERAPY; DRUG; PARADIGM SHIFT; SOFTWARE; TOXIC MATERIAL; VITAMIN;

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID;

HUMAN; PROMYELOCYTIC LEUKEMIA; REVIEW;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TRETINOIN;

EID: 34347384854     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2007.2026     Document Type: Review

References (103)

1. Ahn, Y. O., Koo, H. H., Park, B. J., Yoo, K. Y. & Lee, M. S. 1991 Incidence estimation of leukemia among Koreans. J. Korean Med. Sci. 6, 299-307.
2. Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C. & Gronemeyer, H. 2001 Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand trail. Nat. Med. 7, 680-686. (doi:10.1038/89050)
3. Arnould, C., Philippe, C., Bourdon, V., Gregoire, M. J., Berger, R. & Jonveaux, P. 1999 The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum. Mol. Genet. 8, 1741-1749. (doi:10.1093/ hmg/8.9.1741)
4. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R. & Sultan, C. 1976 Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br. J. Haematol. 33, 451-458.
5. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R. & Sultan, C. 1980 A variant form of hypergranular promyelocytic leukaemia (M3). Br. J. Haematol. 44, 169-170.
6. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R. & Sultan, C. 1985 Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American- British cooperative group. Ann. Intern. Med. 103, 620-625.
7. Bernard, J., Mathe, G., Boulay, J., Ceoard, B. & Chome, J. 1959 Acute promyelocytic leukemia: a study made on 20 cases. Schweiz Med. Wochenschr. 89, 604-608.
8. Bernard, J., Weil, M., Boiron, M., Jacquillat, C., Flandrin, G. & Gemon, M. F. 1973 Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41, 489-496.
9. Bernardi, R. & Pandolfi, P. P. 2003 Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22, 9048-9057. (doi:10.1038/sj.onc. 1207106)
10. Breitman, T. R., Selonick, S. E. & Collins, S. J. 1980 Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl Acad. Sci. USA 77, 2936-2940. (doi:10.1073/pnas.77.5. 2936)
11. Breitman, T. R., Collins, S. J. & Keene, B. R. 1981 Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57, 1000-1004.
12. Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S. & Bishop, J. M. 1997 A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551-2556. (doi:10.1073/pnas.94.6.2551)
13. Caen, J., Mathe, G., Xuan Chat, L. & Bernard, J. 1957 Etude de la fibrinolyse au cours des hemopathies malignes. In Transcripts of the Sixth Congress of the European Society of Hematology, Copenhagen, pp. 502-506.
14. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P. & Degos, L. 1990 All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76, 1704-1709.
15. Chan, K. W., Steinherz, P. G. & Miller, D. R. 1981 Acute promyelocytic leukemia in children. Med. Pediatr. Oncol. 9, 5-15.
16. Chen, S. J., Zelent, A., Tong, J. H., Yu, H. Q., Wang, Z. Y., Derre, J., Berger, R., Waxman, S. & Chen, Z. 1993a Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J. Clin. Invest. 91, 2260-2267.
17. Chen, Z., Brand, N. J., Chen, A., Chen, S. J., Tong, J. H., Wang, Z. Y., Waxman, S. & Zelent, A. 1993b Fusion between a novel kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 12, 1161-1167.
18. 3 induces nb4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88, 1052-1061.
19. 3 exerts dose-dependent dual effects on APL cells. Blood 89, 3345-3353.
20. Chen, Z., Chen, G. Q., Shen, Z. X., Chen, S. J. & Wang, Z. Y. 2001 Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin. Hematol. 38, 26-36. (doi:10.1053/shem.2001.20863)
21. Cordonnier, C. et al. 1985 Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 55, 18-25. (doi:10.1002/1097-0142(19850101)55:1 〈18::AID-CNC R2820550104〉 3.0.CO;2-B)
22. Corey, S. J., Locker, J., Oliveri, D. R., Shekhter-Levin, S., Redner, R. L., Penchansky, L. & Gollin, S. M. 1994 A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia 8, 1350-1353.
23. Degos, L. 2003 The history of acute promyelocytic leukaemia. Br. J. Haematol. 122, 539-553. (doi:10.1046/ j.1365-2141.2003.04460.x)
24. Dong, S. et al. 1996 Ammo-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc. Natl Acad. Sci. USA 93, 3624-3629. (doi:10.1073/pnas.93.8.3624)
25. Drapkin, R. L., Gee, T. S., Dowling, M. D., Arlin, Z., McKenzie, S., Kempin, S. & Clarkson, B. 1978 Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 41, 2484-2490. (doi:10.1002/1097- 0142(197806) 41:6 〈2484::AID-CNCR2820410659〉 3.0.CO;2-)
26. Elliott, S. et al. 1992 Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79, 1916-1919.
27. Fenaux, P. et al. 2000 Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 14, 1371-1377. (doi:10.1038/sj.leu. 2401859)
28. Fibach, E., Hayashi, M. & Sachs, L. 1973 Control of normal differentiation of myeloid leukemic cells to macrophages and granulocytes. Proc. Natl Acad. Sci. USA 70, 343-346. (doi:10.1073/pnas.70.2.343)
29. Gianni, M., Koken, M. H., Chelbi-Alix, M. K., Benoit, G., Lanotte, M., Chen, Z. & de The, H. 1998 Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91, 4300-4310.
30. Gianni, M., Ponzanelli, I., Mologni, L., Reichert, U., Rambaldi, A., Terao, M. & Garattini, E. 2000 Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ. 7, 447-460. (doi:10.1038/sj.cdd.4400673)
31. Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G. & Ley, T. J. 1997 Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 89, 376-387.
32. Guillemin, M. C. et al. 2002 In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373-1380. (doi:10.1084/jem.20021129)
33. Hayakawa, F. & Privalsky, M. L. 2004 Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389-401. (doi:10.1016/S1535-6108(04) 00082-0)
34. He, L. Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G. & Pandolfi, P. P. 1997 Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl Acad. Sci. USA 94, 5302-5307. (doi:10.1073/pnas.94.10.5302)
35. Hillestad, L. K. 1957 Acute promyelocytic leukemia. Acta Med. Scand. 159, 189-194.
36. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., Gu, L. J. & Wang, Z. Y. 1988 Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572.
37. Huang, X. J., Wiernik, P. H., Klein, R. S. & Gallagher, R. E. 1999 Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med. Oncol. 16, 58-64.
38. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J. & Thun, M. J. 2005 Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30.
39. Jensen, K., Shiels, C. & Freemont, P. S. 2001 PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223-7233. (doi:10.1038/sj.onc.1204765)
40. Jing, Y., Wang, L., Xia, L., Chen, G. Q., Chen, Z., Miller, W. H. & Waxman, S. 2001 Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97, 264-269. (doi:10.1182/blood.V97.1.264)
41. Kamashev, D., Vitoux, D. & de The, H. 2004 PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J. Exp. Med. 199, 1163-1174. (doi:10.1084/jem. 20032226)
42. Kantarjian, H. M. et al. 1986 Acute promyelocytic leukemia. M. D. Anderson hospital experience. Am. J. Med. 80, 789-797. (doi:10.1016/0002-9343(86)90617-0)
43. Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J. & Gilliland, D. G. 2002 PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl Acad. Sci. USA 99, 8283-8288. (doi:10.1073/pnas.122233699)
44. Kini, A. R., Peterson, L. A., Tallman, M. S. & Lingen, M. W. 2001 Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97, 3919-3924. (doi:10.1182/blood.V97.12.3919)
45. Kogan, S. C., Hong, S. H., Shultz, D. B., Privalsky, M. L. & Bishop, J. M. 2000 Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 95, 1541-1550.
46. Kogan, S. C., Brown, D. E., Shultz, D. B., Truong, B. T., Lallemand-Breitenbach, V., Guillemin, M. C., Lagasse, E., Weissman, I. L. & Bishop, J. M. 2001 BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531-543. (doi:10.1084/jem.193.4.531)
47. Lallemand-Breitenbach, V., Guillemin, M. C., Janin, A., Daniel, M. T., Degos, L., Kogan, S. C., Michael Bishop, J. & de The, H. 1999 Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043-1052. (doi:10.1084/jem.189.7.1043)
48. 3-induced PML or PML/retinoic acid receptor a degradation. J. Exp. Med. 193, 1361-1371. (doi:10.1084/jem.193.12. 1361)
49. Lane, A. A. & Ley, T. J. 2003 Neutrophil elastase cleaves PML-RARα and is important for the development of acute promyelocytic leukemia in mice. Cell 115, 305-318. (doi:10.1016/S0092-8674(03) 00852-3)
50. Li, S. Z. 1982 The compendium of materia medica (originally published in the Ming Dynasty of China, 1578). Beijing, China: People's Medical Publishing House.
51. Licht, J. D., Shaknovich, R., English, M. A., Melnick, A., Li, J. Y., Reddy, J. C., Dong, S., Chen, S. J., Zelent, A. & Waxman, S. 1996 Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene 12, 323-336.
52. Lin, H. K., Bergmann, S. & Pandolfi, P. P. 2004 Cytoplasmic PML function in TGF-beta signalling. Nature 431, 205-211. (doi:10.1038/nature02783)
53. 3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL). Blood 108, 170a.
54. Liu, T. X. et al. 2000 Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 96, 1496-1504.
55. Lu, D. P., Qiu, J. Y., Jiang, B., Wang, Q., Liu, K. Y., Liu, Y. R. & Chen, S. S. 2002 Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99, 3136-3143. (doi:10.1182/blood.V99.9.3136)
56. Marill, J., Idres, N., Capron, C. C., Nguyen, E. & Chabot, G. G. 2003 Retinoic acid metabolism and mechanism of action: a review. Curr. Drug Metab. 4, 1-10. (doi:10.2174/ 1389200033336900)
57. Martin, S. J., Bradley, J. G. & Cotter, T. G. 1990 HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin. Exp. Immunol. 79, 448-453.
58. McKenna, R. W., Parkin, J., Bloomfield, C. D., Sundberg, R. D. & Brunning, R. D. 1982 Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br. J. Haematol. 50, 201-214.
59. Melnick, A. & Licht, J. D. 1999 Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-3215.
60. Miller Jr, W. H., Schipper, H. M., Lee, J. S., Singer, J. & Waxman, S. 2002 Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903.
61. Muller, S., Matunis, M. J. & Dejean, A. 1998 Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70. (doi:10.1093/emboj/17.1.61)
62. Nervi, C. et al. 1998 Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood 92, 2244-2251.
63. Niu, C. et al. 1999 Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94, 3315-3324.
64. Paran, M., Sachs, L., Barak, Y. & Resnitzky, P. 1970 In vitro induction of granulocyte differentiation in hematopoietic cells from leukemic and non-leukemic patients. Proc. Natl Acad. Sci. USA 67, 1542-1549. (doi:10.1073/pnas.67.3. 1542)
65. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. 2005 Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
66. Quignon, F., De, B. F., Koken, M., Feunteun, J., Ameisen, J. C. & de The, H. 1998 PML induces a novel caspase-independent death process. Nat. Genet. 20, 259-265. (doi:10.1038/3068)
67. Raelson, J. V., Nervi, C., Rosenauer, A., Benedetti, L., Monczak, Y., Pearson, M., Pelicci, P. G. & Miller, W. J. 1996 The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88, 2826-2832.
68. Raffoux, E. et al. 2003 Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J. Clin. Oncol. 21, 2326-2334. (doi:10.1200/JCO.2003. 01.149)
69. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10 173-10 178. (doi:10.1073/pnas.180290497)
70. Rocca, B., Morosetti, R., Habib, A., Maggiano, N., Zassadowski, F., Ciabattoni, G., Chomienne, C., Papp, B. & Ranelletti, F. O. 2004 Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation. Leukemia 18, 1373-1379. (doi:10.1038/sj.leu.2403407)
71. Rowley, J. D., Golomb, H. M. & Dougherty, C. 1977 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1, 549-550. (doi:10. 1016/S0140-6736(77)91415-5)
72. Ruchaud, S., Duprez, E., Gendron, M. C., Houge, G., Genieser, H. G., Jastorff, B., Doskeland, S. O. & Lanotte, M. 1994 Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc. Natl Acad. Sci. USA 91, 8428-8432. (doi:10.1073/pnas.91.18. 8428)
73. Runde, V., Aul, C., Sudhoff, T., Heyll, A. & Schneider, W. 1992 Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. Ann. Hematol. 64, 270-272. (doi:10.1007/BF01695469)
74. Sachs, L. 1978a Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 274, 535-539. (doi:10.1038/274535a0)
75. Sachs, L. 1978b The differentiation of myeloid leukaemia cells: new possibilities for therapy. Br. J. Haematol. 40, 509-517.
76. Salomoni, P. & Pandolfi, P. P. 2002 The role of PML in tumor suppression. Cell 108, 165-170. (doi:10.1016/S0092-8674(02)00626- 8)
77. Sanz, M. A. et al. 1988 Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 61, 7-13. (doi:10.1002/1097-0142(19880101)61:1 〈7::AID-CNCR 2820610103〉 3.0.CO;2-6)
78. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360.
79. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 101, 5328-5335. (doi:10.1073/pnas. 0400053101)
80. Shih, L. Y., Kuo, M. C., Liang, D. C., Huang, C. F., Lin, T. L., Wu, J. H., Wang, P. N., Dunn, P. & Lai, C. L. 2003 Internal tandem duplication and ASP835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 98, 1206-1216. (doi:10. 1002/cncr.11636)
81. Slack, J. L., Waxman, S., Tricot, G., Tallman, M. S. & Bloomfield, C. D. 2002 Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 7, 1-13. (doi:10.1634/theoncologist.7-suppl_1-1)
82. Sohal, J. et al. 2003 A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101, 3188-3197. (doi:10.1182/ blood-2002-06-1800)
83. Soignet, S. L. et al. 1998 Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341-1348. (doi:10.1056/NEJM199 811053391901)
84. Soignet, S. L. et al. 2001 United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19, 3852-3860.
85. Sun, H. D., Ma, L., Hu, X. C. & Zhang, T. D. 1992 Ai-lin 1 treated 32 cases of acute promyelocytic leukemia. Chin. J. Integr. Chin. West Med. 12, 170-171.
86. Tallman, M. S. et al. 1997 All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337, 1021-1028. (doi:10.1056/NEJM199710093371501)
87. Tallman, M. S., Nabhan, C., Feusner, J. H. & Rowe, J. M. 2002 Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99, 759-767. (doi:10.1182/blood.V99.3. 759)
88. vom Baur, E. et al. 1996 Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15, 110-124.
89. Wang, Z. Y. 2003 Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology (Am. Soc. Hematol. Educ. Program), 1-13.
90. Warrell, R. P. et al. 1991 Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324, 1385-1393.
91. Warrell, R. P., de The, H., Wang, Z. Y. & Degos, L. 1993 Acute promyelocytic leukemia. N. Engl. J. Med. 329, 177-189. (doi:10.1056/NEJM199307153290307)
92. Wells, R. A., Hummel, J. L., De, K. A., Zipursky, A., Kirby, M., Dube, I. & Kamel-Reid, S. 1996 A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation. Leukemia 10, 735-740.
93. Xiao, L., Wang, K., Teng, Y. & Zhang, J. 2003 Component plane presentation integrated self-organizing map for microarray data analysis. FEBS Lett. 538, 117-124. (doi:10.1016/S0014-5793(03)00156-X)
94. Yang, C. & Zhang, X. 1991 Incidence survey of leukemia in China. Chin. Med. Sci. J. 6, 65-70.
95. Zheng, P. Z. et al. 2005 Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/ apoptosis of promyelocytic leukemia. Proc. Natl Acad. Sci. USA 102, 7653-7658. (doi:10.1073/pnas. 0502825102)
96. Zhou, G. B., Zhao, W. L., Wang, Z. Y., Chen, S. J. & Chen, Z. 2005 Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med. 2, 33-38. (doi:10. 1371/journal.pmed.0020012)
97. Zhu, J., Koken, M. H., Quignon, F., Chelbi-Alix, M. K., Degos, L., Wang, Z. Y., Chen, Z. & de The, H. 1997 Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 3978-3983. (doi:10.1073/pnas.94.8. 3978)
98. Zhu, J. et al. 1999a Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 13, 1062-1070. (doi:10.1038/sj/leu/ 2401448)
99. Zhu, X. H. et al. 1999b Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl Cancer Inst. 91, 772-778. (doi:10.1093/jnci/91.9.772)
100. Zhu, J., Lallemand-Breitenbach, V. & de The, H. 2001 Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism: role of oncogene degradation in disease remission. Oncogene 20, 7257-7265. (doi:10.1038/ sj.onc.1204852)
101. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de The, H. 2002a How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2, 705-713. (doi:10.1038/ nrc887)
102. Zhu, Q. et al. 2002b Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99, 1014-1022. (doi:10.1182/blood.V99. 7.2562)
103. Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S. & de The, H. 2005 A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143-153. (doi:10.1016/j.ccr.2005. 01.005)